Post-Marketing Safety Study in ST-Segment Elevation Myocardial Infarction (STEMI) Participants Undergoing Primary Percutaneous Coronary Intervention (PCI) Procedure With VISIPAQUE® as the Contrast Medium
The Association of Iodixanol (Visipaque) to Renal Function and Cardiac and Cerebrovascular Events in STEMI Patients Undergoing Primary PCI: A Prospective, Multi-National, Multi-Center, Open-Label, Observational Study
Sponsor: GE Healthcare
Listed as NCT03671603, this observational or N/A phase trial focuses on Coronary Artery Disease and ST-segment Elevation Myocardial Infarction and remains completed. Sponsored by GE Healthcare, it has been updated 12 times since 2018, reflecting substantial change activity. This study contributes longitudinal data to the cardiovascular research landscape.
Status Flow
Change History
12 versions recorded-
Sep 2025 — Present [monthly]
Completed
-
Sep 2024 — Sep 2025 [monthly]
Completed
-
Jul 2024 — Sep 2024 [monthly]
Completed
-
Feb 2022 — Jul 2024 [monthly]
Completed
-
Sep 2021 — Feb 2022 [monthly]
Completed
Status: Recruiting → Completed
▶ Show 7 earlier versions
-
Jan 2021 — Sep 2021 [monthly]
Recruiting
-
Aug 2020 — Jan 2021 [monthly]
Recruiting
-
Jan 2020 — Aug 2020 [monthly]
Recruiting
-
Feb 2019 — Jan 2020 [monthly]
Recruiting
-
Jan 2019 — Feb 2019 [monthly]
Recruiting
Status: Not Yet Recruiting → Recruiting
-
Nov 2018 — Jan 2019 [monthly]
Not Yet Recruiting
-
Oct 2018 — Nov 2018 [monthly]
Not Yet Recruiting
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- GE Healthcare
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
Ankang, China , Beijing, China , Changchun, China , Changsha, China , Chengdu, China , Chongqing, China , Fenyang, China , Guangdong, China , Guangzhou, China , Kaifeng, China and 15 more locations